purpose evaluate incidence pattern hypopituitarism hypothalamic ht pituitary gland pg damage following conformal fractionated beam radiotherapy pprt base skull bos region adults relationship dose volume pg function explored methods materials NUMBER october NUMBER NUMBER adults neoplasms predominantly chordoma chondrosarcomas bos treated pprt subtotal resections median age NUMBER years range NUMBER males NUMBER females median prescribed target dose NUMBER cobalt gray equivalent cge range cge cge fraction day cge proton gy x NUMBER ht pg outlined planning ct scans allow histograms dvh analysis patients baseline clinical testing anterior posterior pituitary function including biochemical assessment thyroid adrenal gonadal function prolactin secretion results actuarial overall survival rate NUMBER median endocrine time NUMBER years majority patients available followup actuarial rates endocrinopathy follows NUMBER hyperprolactinemia NUMBER hypothyroidism NUMBER hypogonadism NUMBER hypoadrenalism respective endocrinopathy rates NUMBER NUMBER NUMBER NUMBER patient developed diabetes insipidus vasopressin deficiency growth hormone deficiency routinely followed study minimum target dose dmin pg predictive endocrinopathy patients receiving NUMBER cge greater dmin pg experiencing higher incidence severity defined number endocrinopathies occurring patient endocrine dysfunction dmax NUMBER cge greater pg dmax NUMBER cge greater ht predictive higher rates endocrine dysfunction conclusion damage ht pg occurs frequently pprt bos manifested anterior pituitary gland dysfunction hyperprolactinemia detected majority patients posterior pituitary dysfunction represented vasopressin activity diabetes insipidus observed dose range limiting dose ht pg feasible reduce risk developing clinical hypopituitarism high dose proton photon non pg non ht NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER dose volume follow NUMBER year follow long term year NUMBER year radiation induced high dose